Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Here, we present a method to identify compounds that modulate the ADCC mechanism, an important cancer cell-killing mechanism of antitumor antibodies. The cytotoxic effect of NK cells is measured in breast cancer cell spheroids in the presence of Trastuzumab. Image analysis identifies live and dead killer and target cells in spheroids.

Abstract

Monoclonal antibody-based immunotherapy targeting tumor antigens is now a mainstay of cancer treatment. One of the clinically relevant mechanisms of action of the antibodies is antibody-dependent cellular cytotoxicity (ADCC), where the antibody binds to the cancer cells and engages the cellular component of the immune system, e.g., natural killer (NK) cells, to kill the tumor cells. The effectiveness of these therapies could be improved by identifying adjuvant compounds that increase the sensitivity of the cancer cells or the potency of the immune cells. In addition, undiscovered drug interactions in cancer patients co-medicated for previous conditions or cancer-associated symptoms may determine the success of the antibody therapy; therefore, such unwanted drug interactions need to be eliminated. With these goals in mind, we created a cancer ADCC model and describe here a simple protocol to find ADCC-modulating drugs. Since 3D models such as cancer cell spheroids are superior to 2D cultures in predicting in vivo responses of tumors to anticancer therapies, spheroid co-cultures of EGFP-expressing HER2+ JIMT-1 breast cancer cells and the NK92.CD16 cell lines were set up and induced with Trastuzumab, a monoclonal antibody clinically approved against HER2-positive breast cancer. JIMT-1 spheroids were allowed to form in cell-repellent U-bottom 96-well plates. On day 3, NK cells and Trastuzumab were added. The spheroids were then stained with Annexin V-Alexa 647 to measure apoptotic cell death, which was quantitated in the peripheral zone of the spheroids with an automated microscope. The applicability of our assay to identify ADCC-modulating molecules is demonstrated by showing that Sunitinib, a receptor tyrosine kinase inhibitor approved by the FDA against metastatic cancer, almost completely abolishes ADCC. The generation of the spheroids and image acquisition and analysis pipelines are compatible with high-throughput screening for ADCC-modulating compounds in cancer cell spheroids.

Introduction

Multicellular tumor spheroids (MCTS) are widely used three-dimensional (3D) models that form due to the tendency of adherent cells to aggregate and represent an important tool for gaining mechanistic insight into cancer cell biology. They can be generated from a broad range of cell types by numerous techniques, such as liquid-based and scaffold-based 3D cultures1. Their main advantage over monolayer 2D models is that they recapitulate the main features of in vivo tumors, namely structural organization and hypoxia, by mimicking the biological behavior of tumor cells, especially the mechanisms leading to therapeutic escape and drug resis....

Protocol

1. Setting up the JIMT-1-enhanced fluorescent protein (EGFP) spheroid model

  1. To form a U-shaped cell-repellent bottom, coat the 96-well plate with 0.5% agarose-PBS solution (30 µL/well). Incubate the plate at room temperature for approximately 30-45 min.
  2. Wash the JIMT-1-EGFP cells twice with 2 mL of sterile PBS (generation of JIMT1-EGFP cell line was reported in a previous publication17). Use T25 tissue culture flasks and JIMT-1 media (DMEM/F-12 medium su.......

Representative Results

EGFP expressing JIMT-1 cells were generated, and spheroids were grown from these cells. Sunitinib was used as a test compound as it was previously shown to affect the course of ADCC17. Spheroids were allowed to clump for 72 h. On day 3, 10 µg/mL of Trastuzumab (or equimolar 6.6 µg/mL TR-F(ab')219) and NK cells (20:1) were added to the spheroids in the presence or the absence of 20 µM Sunitinib (1 h pre-treatment), for a total time of 24 h. JIMT.......

Discussion

Despite significant improvements in treating BC over the past several decades, patients still regularly develop medication resistance or experience negative side effects24. The high morbidity and mortality linked to BC demand a continuing investigation into the underlying molecular mechanisms, just as robust screening platforms to identify new molecules actionable for therapeutic development25. These strategies require cell culture-based translational assays. 3D tumor cultu.......

Acknowledgements

LV received funding from National Research, Development and Innovation Office grants GINOP-2.3.2-15-2016-00010 TUMORDNS", GINOP-2.3.2-15-2016-00048-STAYALIVE, OTKA K132193 and K147482. This project has received funding from the HUN-REN Hungarian Research Network. CD16.176V.NK-92 cells were obtained from Dr. Kerry S. Campbell (Fox Chase Center, Philadelphia, PA, on behalf of Brink Biologics, lnc. San Diego, CA), are protected by patents worldwide, and were licensed by Nantkwest, lnc. (www.nantkwest.com). Authors are thankful to György Vereb and Árpád Szöőr for their help with the use of the NK-92 cell line and the TR-F(ab’)2

Materials

NameCompanyCatalog NumberComments
96-well glass bottom Cell Carrier Ultra microplatesPerkinElmer, Waltham, MA, USALLC 6055302for spheroids measurements
96-well tissue culture platesTPP92096for cell seeding
α-MEM mediumSigmaM8042in NK medium
AgaroseSigmaA9539for spheroids seeding
Annexin V-Alexa Fluo 647 conjugateInvitrogen-ThermoFisher ScientificA23204for apoptosis measurement with HCS
CD16.176 V.NK-92 cellsDr. Kerry S. Campbell (the Fox Chase Cancer Center, Philadelphia, PA on behalf of Brink Biologics, Inc. San Diego, CA)ATCC CRL-2407for cell culture
Cell Tracker BlueInvitrogen-Thermo Scientific, Waltham, MA, USA)C2110for staining of NK cells
DMEM/F-12 mediumSigmaD8437in JIMT1-EGFP medium
Dimethyl sulfoxide (DMSO)SigmaD8418for coating HCS plate before transfering the spheroids
Fetal bovine serum (FBS)BioseraFB-1090/500JIMT-1-EGFP and NK medium
GlutamineGibco35,050–061in NK medium
GraphPad Prism 8.0.1GraphPad Software Inc., San Diego, CA, USAfor statistical analysis
Harmony softwarePerkinElmer, Waltham, MA, USAfor HCA
IL-2Proleukin, Novartis Hungária Kft., Budapest, HungaryPHC0026in NK medium
Insulin (Humulin R)Eli LillyHI0219JIMT-1-EGFP medium
JIMT-1 breast cancer cellsfor cell culture
MEM Non-essential Amino Acids (MEM-NEAA)Gibco11,140–050in NK medium
Na-pyruvateLonzaBE13-115Ein NK medium
Opera Phenix High-Content Analysis equipmentPerkinElmer, Waltham, MA, USAHH14001000for HCA
PBS (Posphate buffered saline)LonzaBE17-517Qfor washing the cells
Penicillin-StreptomycinBioseraLM-A4118JIMT-1-EGFP and NK medium
pLP-1, pLP-2, pLP-VSV-G, pWOXEGFPInvitrogen, (Prof. József Tfigure-materials-3101zsér, University of Debrecen)for JIMT-1-EGFP cell line
Pluronic-F127SigmaP2443for coating HCS plate before transfering the spheroids
Sunitinib malateSigmaAldrichPZ0012for treatments
Trastuzumab Ab (humanized anti-HER2 monoclonal antibody)Herzuma®, EGIS Pharmaceuticals, Budapest, HungaryNDC-63459-303-43for treatments
Trastuzumab-F(ab')2Gift from Prof. György Vereb and Árpád Szöfigure-materials-3870Department of Biophysics and Cell Biology, University of Debrecenfor treatments
Trypan blue 0.4% solutionSigmaT8154for cell counting
Trypsin-EDTA 1X in PBSBioseraLM-T1706for cells detachment

References

Explore More Articles

Antibody dependent Cellular CytotoxicityADCCTumor Spheroid ModelDrug DiscoveryAnti HER2 AntibodyTrastuzumabNatural Killer CellsNK Cells3D ModelJIMT 1 Breast Carcinoma CellsGFP96 well PlateAgarose CoatingSpheroid FormationPluronic F 127 CoatingHigh content Screening

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved